The successful clinical implementation of cell and gene therapy (CGT) requires dependable point-of-care approaches, to ensure the delivery of high-quality cell products to patients in need. Standardized in-process and quality controls (IPC/QC) that enable compliance with regulatory guidelines are therefore critical for reliable assessment of the safety and efficacy of cellular therapies throughout cell manufacturing workflows.
Join us to learn more about how to optimize point-of-care practices, focusing on analytical development and release testing. Learn about the importance of easy-to-implement strategies to streamline IPC/QC methodologies and take the opportunity to get expert insights on the latest advancements in CGT.
Don’t miss the chance to: